NCT03436563
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MSI-H
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are eligible for cohort C, but must have tumors that express MSI-H; Patient must have had disease progression following prior immune checkpoint blockade therapy
Exclusions: Patients with known untreated symptomatic brain metastases that require treatment – see trial for details
https://ClinicalTrials.gov/show/NCT03436563